SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckins Mubadala-backed investment and potential Gulf expansion are driving discussion, with traders viewing the sovereign funds involvement as a sign of institutional support and a possible step toward broader international growth. That optimism is tempered by frustration over the stocks weak, range-bound trading and speculation about buybacks and a future U.S. relisting, for which no timeline is established.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Branded and ImprimisRx. The Branded segment includes activities of the company’s FDA approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain branded products. The ImprimisRx segment represents activities in the company’s ophthalmology-focused pharmaceutical compounding business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrows selloff is drawing attention amid investor frustration with repeated revenue and guidance misses, management execution, and uncertainty over VEVYEs ability to turn prescription growth into revenue. Long-term bulls still see potential in the expanding ophthalmology portfolio, but skeptics say the company needs to rebuild credibility with consistent results.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ousters Rev8 lidar is drawing attention as partners integrate it into autonomous applications, including wildfire-response drones, aerial mapping, and driverless orchard equipmentsupporting the communitys broader growth thesis around robotics and infrastructure sensing. Traders are bullish on expanding real-world use cases, but some remain frustrated by volatile trading and question how quickly deployments can scale.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivaxs sharp pullback and the absence of a confirmed takeover dominate discussion, with traders split between expecting a Big Pharma bid and viewing the stock as potentially stalled while the company advances obefazimod toward an ulcerative-colitis filing and Crohns data. A French filing reportedly showing Helikon increased its stake also drew attention, but takeover speculation remains unconfirmed.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

Axons proposed $1 billion offering of zero-coupon convertible notes has fueled concern about potential dilution and contributed to a sharp selloff. Traders are split between viewing the financing as a shareholder risk and seeing it as low-cost growth capital, with the stocks volatile rebound drawing further attention.

Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis Corp 

A DEA administrative-law pause in the broader cannabis rescheduling process, prompted by questions about federal review procedures, has driven debate and volatility in cannabis stocks. Traders disagree over whether the pause is a temporary procedural delay or a setback to Schedule III and related tax relief; some see Trulieves medical-cannabis exposure as cushioning the impact, while others note it sold off with the sector.

Injective is an interoperable Layer 1 blockchain designed for DeFi applications. It provides developers with on-chain financial infrastructure modules to build dApps such as decentralized exchanges, prediction markets, and lending protocols. Its decentralized cross-chain bridging infrastructure offers compatibility with most blockchains, including EVM chains like Ethereum and non-EVM chains like Solana.

Injective

Injectives RWA and institutional-finance expansionincluding tokenized assets and its SEC transfer-agent statusis drawing attention alongside discussion of buybacks and a proposed supply-squeeze change that could increase INJs deflation rate if approved. Bulls view these developments as support for a recovery, while skeptics point to the tokens prolonged weakness and question whether the adoption will translate into demand.

KraneShares Trust - KraneShares CSI China Internet ETF

KraneShares CSI China Internet ETF

A modest rebound in Chinese internet stocks has revived discussion of a possible oversold bounce and rotation into China tech, with traders pointing to support and bullish options activity. Others argue the ETF remains in a broader downtrend, citing China-market weakness, policy risks, and persistent underperformance; no single confirmed catalyst dominates.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. The firm offers various products for application security, performance and reliability, network services, Zero Trust, developer platform, media delivery, insights, domain registration, and consumer services. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

Cloudflares strong earnings and raised outlook, alongside optimism about its AI-agent and cybersecurity infrastructure, are supporting a momentum and new-highs conversation. Bulls point to growth potential and analyst optimism, while skeptics argue the valuation is stretched and warn of a pullback.

Hyperliquid is a layer one (L1) blockchain best known for perpetual futures and spot trading. Beyond its flagship DEX trading platform, the ecosystem supports borrowing, lending, real world assets (RWAs), and a full-fledged Ethereum Virtual Machine (EVM), making it a leading force in decentralized finance (defi).   Just as electronic trading dramatically improved markets in the 2000s, Hyperliquid offers an opportunity for a massive technical upgrade of the existing financial system through a transparent, efficient, and resilient blockchain. HYPE is the native token of the Hyperliquid blockchain, with a maximum supply of 1 billion.

Hype

Hyperliquids fee-funded token buybacks and burns are a key bullish theme, with traders also focused on HYPEs recent rally and tests of record highs. Sentiment is divided between dip-buyers expecting the uptrend to continue and traders warning of a pullback amid token-supply concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Down 22% in 4 Weeks, Here's Why Innate Pharma (IPHA) Looks Ripe for a Turnaround 

Innate Pharma (IPHA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down 25% in 4 Weeks, Here's Why You Should You Buy the Dip in Innate Pharma (IPHA)

Innate Pharma (IPHA) Upgraded to Buy: Here's What You Should Know

Innate Pharma (IPHA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Innate Pharma (IPHA) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Innate Pharma Reports First Half 2026 Business Update and Financial Results

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today reported its consolidated financial results for the six months ended June 30, 2026. The consolidated financial statements are attached to this press release. 2026 continues to be an important year of...

Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that the previously announced strategic partnership with Sobi is now effective following the expiration of applicable antitrust waiting periods and completion of other conditions. As...

Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), today announced that the Company will hold a conference call on Thursday, September 17, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT, to provide a business update for the first half of 2026. Participants in the...

Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in a fireside chat and one-on-one investor...

Innate Pharma Announces Conference Call and Webcast

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), today announces that the Company will hold a conference call on Friday, August 14, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT. Participants during the call will be: Jonathan Dickinson, Chief Executive Officer...

Innate Pharma Jumps as Sobi Deal Boosts Secured Financing for Advancing Rare Skin Cancer Therapy

Sobi and Innate Pharma partner for a Phase 3 trial of lacutamab targeting rare skin cancer, featuring a $75 million upfront payment.read more...

Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

Innate Pharma - ADR

IPHA Stock Soars Pre-Market After FDA Clears Late-Stage Trial For Lacutamab In Rare Skin Cancers

Equity

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

Innate Pharma

$IPHA Does this thing have a pulse?  30 min in and 5k shares on a 1.50 stock.   NP. Much LOVE for FRANCE.

Michael Vogel

$IPHA Q2 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.12 up 14.29% YoY
• Reported revenue of $3.23M up 12.94% YoY

Feed

News

Sentiment

Earnings

Fundamentals

Info

IPHA Innate Pharma

Fundamentals

Latest IPHA News